摘要
目的探讨早期应用低分子肝素对慢性阻塞性肺疾病急性加重期（AECOPD）临床疗效的影响。方法根据中华医学会呼吸病学分会慢性阻塞性肺疾病学组制订的COPD诊断标准，纳入哈尔滨医科大学附属第四医院呼吸内科2009年8月-2012年10月明确诊断AECOPD的连续病例140例，随机分为对照组（70例）和抗凝组（70例）。对照组患者均采用常规治疗；抗凝组除常规治疗，同时腹部皮下注射低分子肝素，1次／d，10d为一个疗程。所有患者在治疗前后均进行动脉血气分析、D-二聚体、肺功能检测，并统计住院天数。结果AECOPD患者早期低分子肝素与常规治疗联合应用较常规治疗，明显纠正凝血功能，改善肺功能，纠正低氧和二氧化碳潴留，缩短住院天数。结论AECOPD早期低分子肝素与常规治疗联合应用可明显提高临床疗效。
Objective To investigate clinical efficacy of intervention with low-molecular-weight- heparin （LMWH） on acute exacerbation of chronic obstructive pulmonary disease. Methods According to COPD diagnostic criteria developed by the Chinese Medical Association Hospital of Harbin Medical University,a total of Fourth Affiliated Hospital of Haerbin Medical University from August 2009 to October 2012. All patients were randomly divided into the control group and the anticoagulation group; meanwhile,the patients of the former group were treated with conventional therapy; In addition to conventional therapy, anticoagulation group received low molecular weight heparin by abdominaI subcutaneous injection once every day, with ten days for a course. Before and after treatment, the both groups were detected arterial blood gas analysis,D-dimer,lung function, and to add up hospital day. Results The combination of conventional therapy with low-molecular-weight heparin anticoagulation improved the blood coagulation and pulmonary functions of patients, and corrected bypoxia and carbon dioxide retention, to shorten the hospital day. Conclusions The combination of conventional therapy with low- molecular-weight heparin anticoagulation can significantly improve the clinical efficacy in acute exacerbation of chronic obstructive pulmonary disease early.
出处
《国际呼吸杂志》
2014年第11期827-830,共4页
International Journal of Respiration
基金
黑龙江省留学归国科学基金项目（LC201024）
关键词
低分子肝素
慢性阻塞性肺疾病
临床疗效
Low molecular weight heparin
Chronic obstructive pulmonary disease
Clinical efficacy
